Health Care/Hospital
Study Shows Ubie Symptom Checker Accuracy Rivals Physicians, Outperforms Competitors In Providing Disease Information
* Results show Ubie's differential diagnosis platform had a Top-5 hit accuracy of 63.4% and a Top-10 hit accuracy of 71.6%; median physician accuracy was 72.9% * Ubie is effective in providing relevant information based on symptoms, making it valuable in speeding diagnosis and care delivery f...
2024-09-10 21:30
1003
Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024
* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker for predicting efficacy of Nivolumab plus Chemotherapy in advanced gastric cancer, independent of PD-L1 status SEOUL, South Korea, Sept. 10, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provi...
2024-09-10 21:00
1448
Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial
NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced promising clinical data from an Investigator-Initiated Trial (IIT) of RAG-17, a small interfering RNA (siRN...
2024-09-10 20:00
1333
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients - Randomized Phase 2 st...
2024-09-10 19:00
932
The 2024 International (Bozhou) TCM Expo Kicked Off
BOZHOU, China, Sept. 10, 2024 /PRNewswire/ -- On the morning of September 9, the 2024 International (Bozhou) TCM Expo and the 40th National (Bozhou) TCM Trade Fair officially kicked off in Bozhou,Anhui Province. In recent years, Bozhou has been enhancing mechanisms for the inheritance, innovatio...
2024-09-10 17:55
861
Xiao-I Corporation and the National Association of the Deaf Partner to Enhance Accessible Communication for Deaf Individuals with AI Technology
SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Xiao-I Corporation (NASDAQ: AIXI) ("Xiao-I" or the "Company"), a leading artificial intelligence company, announces that it signed a strategic partnership with the National Association of the Deaf (the "NAD"), a premier American organization dedicated to im...
2024-09-09 21:45
1681
Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation
BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately$15 ...
2024-09-09 21:09
1110
Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing
* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solution...
2024-09-09 21:00
1338
Neurophet-NTU Singapore, recognized for outstanding joint research
- Neurophet accelerates global expansion for research and partnership in AI-driven brain image analysis SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that Neurophet and NTU (Nanyang Technological Univers...
2024-09-09 21:00
1444
GenAssist Ltd Announced the First DMD Patient Dosed with its Base Editing Drug
SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- On September 06, 2024, GenAssist Ltd (GenAssist), announced the first DMD patient dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). "This is the first-in-human trial for DMD gene editing therapy. It marks t...
2024-09-09 21:00
1157
MGI Launches New Nanopore Sequencing Products with Advanced CycloneSEQ Technology
SHENZHEN, China, Sept. 9, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneS...
2024-09-09 16:24
1183
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
TAIPEI, Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment tothe United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora P...
2024-09-09 15:00
1061
Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024
BOSTON, Sept. 8, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced thatit will present the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2...
2024-09-09 08:30
1076
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024
HONG KONG, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combination with chemotherapy, for the perioperative treatment of ...
2024-09-09 02:17
1405
Bc Babycare Marks a Stellar Debut at Germany's Kind+Jugend 2024
COLOGNE, Germany, Sept. 6, 2024 /PRNewswire/ -- Bc Babycare, a leader in innovative products for mothers and babies, made a remarkable debut at Kind+Jugend 2024, the premier international trade fair for baby and toddler outfitting, which opened inCologne, Germany, on September 3. The brand capti...
2024-09-06 23:22
1777
City of Riyadh Gears Up to Unveil the Future of Healthcare: Global Health Exhibition
* Kingdom of Saudi Arabia to host Global Health Exhibition (21-23 October 2024 ), a major international event at a venue double the size with over 100,000 attendees and 1,200 exhibiting companies and brands to join in Malham,Riyadh * Event will host 500+ expert speakers across multiple healthca...
2024-09-06 12:00
1301
Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies
HONG KONG, Sept. 5, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) will showcase promising results from 13 clinical studies on its internally developed PD-1/CTLA-4 bispecific antibody cadonilimab, PD-1/VEGF bispecific antibody ivonescimab, next-generation CD47 monoclonal antibody ligufalimab, and co...
2024-09-06 08:54
1434
Baird Medical and ExcelFin Acquisition Corp Announce Effectiveness of Registration Statement
FORT MILL, S.C., Sept. 5, 2024 /PRNewswire/ -- Betters Medical Investment
Holdings Limited ("Baird Medical" or the "Company"), a leading microwave
ablation ("MWA") medical device developer and provider inChina, and ExcelFin
Acquisition Corp. ("ExcelFin") (NASDAQ:XFIN
2024-09-06 05:23
2837
A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China
SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval inChina. This groundbreaking achievement is now officially l...
2024-09-05 20:35
1939
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
* Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms * Transactio...
2024-09-05 20:00
2440
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 311 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8699
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5691
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5174
